Literature DB >> 21509215

VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide.

Omayma Elshafie1, Christopher Grant, Aisha Al-Hamdani, Rajeev Jain, Nicholas Woodhouse.   

Abstract

We report the case of a 57-year-old male physician who presented with a life threatening secretory and refractory diarrhoea of around 20 L/day. This was complicated by severe hypotension, hypokalaemia, hypercalcaemia, renal failure requiring dialysis, metabolic acidosis, cardiorespiratory arrest and ventilation for 12 days. His diarrhoea responded immediately to the first dose of a therapeutic trial of subcutaneous octreotide 100 mcg 8 hourly which was started on clinical grounds alone before any investigations were carried out. After one day he was extubated and his blood pressure returned to normal. When a functioning neuroendocrine tumour is suspected clinically, the use of octreotide can, as in this case, be life saving.

Entities:  

Keywords:  Cardiopulmonary arrest; Case report; Chromogranin A; Diarrhoea; Neuroendocrine tumour; Octreotide; Oman; Pancreatic tumour; VIPoma

Year:  2011        PMID: 21509215      PMCID: PMC3074686     

Source DB:  PubMed          Journal:  Sultan Qaboos Univ Med J        ISSN: 2075-051X


  11 in total

Review 1.  Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma.

Authors:  Shu You Peng; Jiang Tao Li; Ying Bin Liu; He Qing Fang; Yu Lian Wu; Chen Hong Peng; Xin Bao Wang; Hao Ran Qian
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

2.  Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia.

Authors:  J V VERNER; A B MORRISON
Journal:  Am J Med       Date:  1958-09       Impact factor: 4.965

3.  Isletcell tumour of the pancreas with peptic ulceration, diarrhoea, and hypokalaemia.

Authors:  W M PRIEST; M K ALEXANDER
Journal:  Lancet       Date:  1957-12-07       Impact factor: 79.321

Review 4.  VIPoma syndrome.

Authors:  H S Mekhjian; T M O'Dorisio
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

5.  Vasoactive intestinal peptide and watery-diarrhoea syndrome.

Authors:  S R Bloom; J M Polak; A G Pearse
Journal:  Lancet       Date:  1973-07-07       Impact factor: 79.321

6.  Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

Authors:  P N Maton; T M O'Dorisio; B A Howe; K E McArthur; J M Howard; J A Cherner; T B Malarkey; M J Collen; J D Gardner; R T Jensen
Journal:  N Engl J Med       Date:  1985-01-03       Impact factor: 91.245

Review 7.  Update on the diagnosis and treatment of rare neuroendocrine tumors.

Authors:  S R Friesen
Journal:  Surg Clin North Am       Date:  1987-04       Impact factor: 2.741

8.  Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases.

Authors:  J Soga; Y Yakuwa
Journal:  J Exp Clin Cancer Res       Date:  1998-12

Review 9.  Pancreatic VIPomas: subject review and one institutional experience.

Authors:  Amir A Ghaferi; Karen A Chojnacki; William D Long; John L Cameron; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

10.  Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide.

Authors:  M G Kane; T M O'Dorisio; G J Krejs
Journal:  N Engl J Med       Date:  1983-12-15       Impact factor: 91.245

View more
  2 in total

Review 1.  Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones.

Authors:  Monjur Ahmed; Sarah Ahmed
Journal:  Gastroenterology Res       Date:  2019-10-04

2.  Prevalence of Diagnostic Methods and Treatment Modalities in Vipoma Patients: A Rare Cause of Hormone-Mediated Diarrhea.

Authors:  Fateme Shamekhi Amiri
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.